CBD and the Bacteria Behind Dental Plaque

What a Laboratory Study Found, and Why It Is Not a Reason to Change Your Routine

Key finding: in laboratory testing, CBD stopped the growth of Streptococcus oralis, one of the first bacteria to colonize a tooth surface and begin building dental plaque, at a concentration of 6.25 micrograms per milliliter. It killed the bacterium outright at 25. At the lower concentrations, human gum cells sitting in the same conditions were unaffected.

That last part is the reason this study is worth a paragraph of your attention rather than a shrug. Killing bacteria is not difficult. Bleach kills bacteria. The hard problem in oral antimicrobials is killing the bacteria while leaving the tissue in your mouth alone, and that is the balance these researchers were testing.

Why researchers keep looking for alternatives

The standard antimicrobial in dentistry is chlorhexidine, and the authors of this study open by noting that agents like it have limited effects. Mechanical cleaning, meaning brushing and scraping, does most of the work; the chemical side has always been the weaker partner. That is the gap natural antimicrobial compounds keep getting tested against, and CBD has been in that queue for several years now.

S. oralis is a sensible target. It is an early coloniser, which means it arrives first and creates the conditions other bacteria build on. Interfering at that stage is a different proposition from attacking an established biofilm, in the same way that clearing a building site is different from demolishing the building.

Biofilm is the reason this is hard. Bacteria growing in a biofilm wrap themselves in a sticky matrix that shields them, and a dose that would kill the same organism swimming freely often does very little once that structure is in place. Anything that interferes with the building of it, rather than waiting to attack the finished product, has an advantage.

What the researchers did

The work was carried out at Université Laval in Quebec and São Paulo State University in Brazil, and published in August 2026 in the International Journal of Dentistry.

S. oralis was grown in the presence of a range of CBD concentrations, and its growth was measured at several points afterwards. Biofilm formation was assessed separately, after three days of exposure, using both histological examination and quantitative analysis. In parallel, human gingival epithelial cells, the cells lining your gums, were exposed to the same CBD concentrations and checked for changes in shape, adhesion, and whether they stayed alive and kept dividing.

The whole study took place in laboratory culture. No person, and no mouth, was involved at any stage. That is worth stating plainly at the outset, because antimicrobial findings are unusually easy to over-read: a number that looks decisive in a dish can fail completely in a living system, where saliva dilutes, tissue absorbs, and hundreds of competing species change the arithmetic.

What they found

• CBD inhibited growth in a concentration-dependent way, with a minimum inhibitory concentration of 6.25 µg/mL and a minimum bactericidal concentration of 25 µg/mL.
• Biofilm formation fell significantly (p < 0.01), and the mechanism was structural: CBD disrupted the architecture of the biofilm rather than simply reducing the bacterial count.
• An effect was visible even at 3.12 µg/mL, the lowest concentration tested, on both growth and biofilm-forming capacity.
• Human gum cells tolerated 3.12, 6.25, and 12.5 µg/mL over 24 hours, with no significant loss of viability or proliferation.

The gap the authors point at themselves

The concentration that killed the bacterium, 25 µg/mL, sits above the range that was tested on the human cells. So the study demonstrates that CBD can inhibit growth and disrupt biofilm at concentrations gum cells tolerate, but it does not demonstrate that the bactericidal concentration is equally well tolerated, because that comparison was not run. The authors state this in their conclusion rather than leaving a reader to work it out, which is a mark in their favour.

What supporting studies add

CBD and CBG against oral bacteria (2024, Antibiotics): A team across universities in Colombia and Brazil tested both cannabinoids against oral organisms and against periodontal ligament cells.

• Against Streptococcus mutans, the bacterium most associated with tooth decay, the minimum inhibitory concentration was 20 µM for CBD and 10 µM for CBG.
• In a 33-species subgingival biofilm, metabolic activity fell 50.38% with CBD at 125 µg/mL (p = 0.03) and 39.9% with CBG at 62 µg/mL (p = 0.023).
• Cell viability held above 95% for CBD and 88% for CBG.
• Neither cannabinoid had any inhibitory effect on Candida albicans, the yeast behind oral thrush. That is a null result and we are reporting it because leaving it out would make the picture look tidier than it is.

CBD against the decay bacterium (2022, International Journal of Molecular Sciences): Researchers at the Hebrew University of Jerusalem examined S. mutans in detail.

• Inhibitory and biofilm-inhibitory concentrations were both 5 µg/mL.
• Confocal microscopy showed a 50-fold decrease in live bacteria and in the sticky extracellular polysaccharide that holds plaque together.
• In biofilms that had already formed, metabolic activity dropped 80 ± 3.1% at 7.5 µg/mL.
• Above 20 µg/mL there was almost no bacterial recovery even 48 hours after the CBD was withdrawn.

Read together, three independent groups in four countries have now found the same broad thing in a dish, using different bacteria and different methods. That consistency is worth something, because independent replication is exactly what separates a promising line of research from a one-off result. It is also still a dish.

What this means for you

The safety picture

Every number above comes from laboratory culture, so there is no safety picture for a person here at all, in either direction. What the studies do show is that at the concentrations where CBD interfered with these bacteria, the human cells tested alongside them stayed viable. That is an encouraging signal for future research and it is not a statement about using anything in your mouth.

The endocannabinoid system is not the mechanism here

Most CBD research we cover concerns the endocannabinoid system, which is present in everyone and helps regulate mood, sleep, appetite, and stress responses. This research is different. The antimicrobial effect appears to be a direct action on bacteria and on the structure of biofilm, not something routed through your receptors. It is a useful reminder that CBD is a molecule with more than one kind of activity, and that a finding in one area tells you nothing about the others. Someone taking CBD for sleep is not thereby doing anything to the bacteria in their mouth, and nothing here suggests they are.

What protects your teeth

Brushing, flossing, and seeing a dentist. Nothing in this research changes that, and nobody involved in it suggests otherwise. If you take one practical thing from this article, let it be that the chemical side of oral care has always been the junior partner to the mechanical side, and that is still true. Mouthwashes and rinses supplement a routine; they have never replaced one, and a laboratory result about a single bacterium does not alter that hierarchy.

Limitations worth knowing

• This is in vitro work. Bacteria in a dish behave differently from bacteria in a mouth, where saliva, temperature, diet, and hundreds of other species all interfere.
• The bactericidal concentration was not tested on human cells. The tolerability finding covers the lower concentrations only.
• One bacterium at a time, mostly. Only the 2024 study used a multi-species biofilm, and the plaque on a tooth is a community of hundreds of species that interact with and protect one another.
• CBD did nothing against Candida albicans. The antimicrobial effect is not general.
• No product exists that delivers these concentrations to a tooth surface, and working out whether one could is a separate research problem that has not been solved.
• Twenty-four hours is a short exposure window for the cell-safety half of the work. Whether gum tissue tolerates repeated contact over weeks or months is untested.

Where that leaves it

The authors describe their own results as preliminary evidence supporting further investigation. That is the correct reading, and it is a considerably more modest claim than the subject invites.

What has changed over the last few years is that the question has moved from whether CBD does anything to oral bacteria, which now looks reasonably settled in the laboratory, to whether that can be turned into something useful in a human mouth. Those are different questions, and the second is much harder: it requires a delivery method, a dose that survives contact with saliva, evidence of tolerability over months rather than a day, and a trial in people with real mouths and real plaque. Nobody has done that work yet. When somebody does, we will cover it, including if the answer turns out to be no.

---

About the Original Study

Title: Cannabidiol (CBD) Inhibits Streptococcus oralis Growth and Biofilm Formation, While Maintaining Human Gingival Epithelial Cell Viability: An In Vitro Study

Published: August 12, 2026, International Journal of Dentistry

Authors:

• Celina Cruz Mainardes (Faculté de Médecine Dentaire, Université Laval, Quebec, Canada)
• Omayma Amri (Faculté de Médecine Dentaire, Université Laval, Quebec, Canada)
• Denise M. Palomari Spolidorio (São Paulo State University, UNESP, Araraquara, Brazil)
• Mahmoud Rouabhia (Faculté de Médecine Dentaire, Université Laval, Quebec, Canada)

Link: https://doi.org/10.1155/ijod/4609857

---